Andera Life Sciences, the business line specialising in innovative therapeutics and medical technologies of the asset management company Andera Partners, has announced the finalisation of its fundraising for its BioDiscovery 6 fund at 456 million euros.

The sixth generation of BioDiscovery funds is consolidating Andera Partners’ position as one of the leading players in life sciences venture capital in Europe. Existing institutional investors of the BioDiscovery funds have chosen to renew their trust in the management team and its strategy and have been joined by new subscribers, which include funds of funds, insurance companies, pension funds, family offices, private investors and pharmaceutical companies.

The new fund will enable the management team to pursue its investment strategy focused on building a balanced portfolio of innovative companies developing therapeutics and medical technologies, at all stages of their development, in Europe and the United States.  To date, BioDiscovery 6 has made six investments in Evommune, Amolyt, TargED, Tubulis, Mineralys and Imcheck.

The Andera Life Sciences partners (Sofia Ioannidou, Olivier Litzka, Gilles Nobécourt, Jan Van den Bossche, Raphaël Wisniewski) comment: “We are honoured by the support of our investors which is strengthening our position as one of the main players in our sector. The acceleration of our funds’ development demonstrates investors’ growing interest in financing medical innovation. For over twenty years, Andera Life Sciences’ support for companies has resulted in over twenty treatments being made available to patients and their doctors. This is the work that we wish to continue.”

Since its inception, the BioDiscovery fund family has raised over 1.1 billion euros and the team has invested in over eighty European and North American therapeutics and medical technology companies, thereby becoming a benchmark in investment dedicated to life sciences. The BioDiscovery funds have generated over forty remarkable exits, including around twenty companies sold, such as Corvidia, Arvelle, Sanifit and ReViral, and around twenty initial public offerings, such as Axonics, Nyxoah and LogicBio.

The Andera Life Sciences team is run by five partners, Sofia Ioannidou, Olivier Litzka, Gilles Nobécourt, Jan Van den Bossche and Raphaël Wisniewski. The team of fourteen professionals brings together in-depth experience of the life sciences industry, private equity and venture capital.

The team has a very large network of international partners, which, coupled with its experience, enables it to be an ideal strategic partner for all innovative companies, providing them with both financial and scientific support at all stages of their growth.

The BioDiscovery 6 fund, classified as Article 8 according to the “European Sustainable Finance Disclosure Regulation (SFDR)” has ambitious targets in terms of CSR. Furthermore, it contributes to the UN Sustainable Development Goals in connection with ‘Health and Well-being’.

Share on :

More news